However, a series of adverse effects (acute kidney injury, injection site reactions, headache, and nasopharyngitis) associated with drugs targeting GLP1R and their involvement in cardiovascular events, pancreatitis, or pancreatic cancer32, may require the identification of novel drug targets. The gene discussed is GLP1R; the disease is acute kidney injury.